# A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy

> **NCT07483827** · PHASE1 · RECRUITING · sponsor: **eleva GmbH** · enrollment: 39 (estimated)

## Conditions studied

- C3 Glomerulopathy (C3G)
- Healthy Adult Participants

## Interventions

- **DRUG:** CPV-104/Placebo
- **DRUG:** CPV-104

## Key facts

- **NCT ID:** NCT07483827
- **Lead sponsor:** eleva GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-26
- **Primary completion:** 2026-06
- **Final completion:** 2026-06
- **Target enrollment:** 39 (ESTIMATED)
- **Last updated:** 2026-04-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07483827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07483827, "A Clinical Trial to Test the Safety, Tolerability, and How the Body Processes CPV-104 in Healthy People and Patients With C3-Glomerulopathy". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT07483827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*